HAD-C 100

General#

Cell Line

hPSCreg Name HADe007-A
Alternative name(s)
HAD-C 100
Cell line type Human embryonic stem cell (hESC)
Last update 19th December 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Hadassah University Hospital (HAD)
Owner Hadassah University Hospital (HAD)
Distributors
Derivation country Israel

External Databases

Cellosaurus CVCL_B860
NIHhESC NIHhESC-11-0123
BioSamples SAMEA6560652

General Information

Notes Cell line is GMP, xeno-free, cell-fragments derived on umbilical-cord fibroblast feeders.
Publications
* Is the cell line readily obtainable for third parties?
Yes
Research: not allowed
Clinical: allowed
Commercial: allowed
Additional restrictions:

Use in research that will not have eventual clinical applications is generally not allowed. Please be in contact with us for further discussions regarding this cell cell line. There is a matching research-grade cell line available.

Donor Information#

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes
Family history No diseases
Is the medical history available upon request? Yes (brief summary of donors' medical history)
Is clinical information available? No health conditions

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA6560651

Ethics#

Was the embryo established purely for research purposes? No
Have both parents consented to the use of the embryo for ESC derivation? Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? No
Alternatives to consent are available? Yes
Alternatives to consent Other information provided sep.
Alternative consent approval number 0123
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? IRB
Approval number 33-26-07.02
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Hadassah ESCRO Committee
Approval number N/A

hESC Derivation#

Date of derivation 2008-09-01
Embryo stage Blastula with ICM and Trophoblast
Supernumerary embryos from IVF treatment?
Yes
Separation of research and IVF treatment?
Yes
PGD Embryo?
No
Expansion status 5
Stephenson 2007
ICM morphology A
Stephenson 2007
Trophectoderm morphology a
Stephenson 2007
Cell isolation Laser
Cell seeding Isolated ICM
Derived under xeno-free conditions?
Yes
Derivation under GMP?
Yes
Available as clinical grade?
Yes

Culture Conditions#

Surface coating Gelatin
Feeder cells umbilical cord fibroblasts
Passage method Enzymatically
TrypLE
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM
Main protein source: Human Serum
Serum concentration: 20 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
SSEA-3
Yes
SSEA-4
Yes
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
TRA 1-81
Yes
hESC Doubling Time (Potency)
Differentiation Potency
Tubulin, Beta
Ont Id: MONDO_0010536
In vivo teratoma
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage:

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
XY Normal
Karyotyping method: G-Banding

Other Genotyping (Cell Line)